JP2016537338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537338A5 JP2016537338A5 JP2016528225A JP2016528225A JP2016537338A5 JP 2016537338 A5 JP2016537338 A5 JP 2016537338A5 JP 2016528225 A JP2016528225 A JP 2016528225A JP 2016528225 A JP2016528225 A JP 2016528225A JP 2016537338 A5 JP2016537338 A5 JP 2016537338A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- treatment
- group
- prodrug
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims 1
- 208000035177 MELAS Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *C([C@](CS1)NC1=O)=O Chemical compound *C([C@](CS1)NC1=O)=O 0.000 description 3
- YTZKOQUCBOVLHL-UHFFFAOYSA-N CC(C)(C)c1ccccc1 Chemical compound CC(C)(C)c1ccccc1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 1
- LEAJWPFHMHVEKV-UHFFFAOYSA-N CCC(c(cccc1)c1OC)=O Chemical compound CCC(c(cccc1)c1OC)=O LEAJWPFHMHVEKV-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020069560A JP6952825B2 (ja) | 2013-11-08 | 2020-04-08 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902052P | 2013-11-08 | 2013-11-08 | |
| US61/902,052 | 2013-11-08 | ||
| US201361902669P | 2013-11-11 | 2013-11-11 | |
| US61/902,669 | 2013-11-11 | ||
| PCT/US2014/064581 WO2015070034A1 (en) | 2013-11-08 | 2014-11-07 | Substituted n-acetyl-l-cysteine derivatives and related compounds |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213633A Division JP6559756B2 (ja) | 2013-11-08 | 2017-11-06 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2020069560A Division JP6952825B2 (ja) | 2013-11-08 | 2020-04-08 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537338A JP2016537338A (ja) | 2016-12-01 |
| JP2016537338A5 true JP2016537338A5 (enExample) | 2017-12-14 |
| JP6691044B2 JP6691044B2 (ja) | 2020-04-28 |
Family
ID=51952031
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528225A Active JP6691044B2 (ja) | 2013-11-08 | 2014-11-07 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2017213633A Active JP6559756B2 (ja) | 2013-11-08 | 2017-11-06 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2020069560A Active JP6952825B2 (ja) | 2013-11-08 | 2020-04-08 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2021156357A Active JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換ｎ－アセチル－ｌ－システイン誘導体及び関連化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213633A Active JP6559756B2 (ja) | 2013-11-08 | 2017-11-06 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2020069560A Active JP6952825B2 (ja) | 2013-11-08 | 2020-04-08 | 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 |
| JP2021156357A Active JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換ｎ－アセチル－ｌ－システイン誘導体及び関連化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US9012674B1 (enExample) |
| EP (2) | EP3066089B1 (enExample) |
| JP (4) | JP6691044B2 (enExample) |
| AU (3) | AU2014346591B2 (enExample) |
| CA (1) | CA2929655C (enExample) |
| DK (1) | DK3066089T3 (enExample) |
| ES (1) | ES2765236T3 (enExample) |
| HU (1) | HUE048345T2 (enExample) |
| LT (1) | LT3066089T (enExample) |
| PL (1) | PL3066089T3 (enExample) |
| PT (1) | PT3066089T (enExample) |
| SI (1) | SI3066089T1 (enExample) |
| WO (1) | WO2015070034A1 (enExample) |
| ZA (1) | ZA201705288B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815905B2 (en) * | 2010-03-10 | 2014-08-26 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
| PL3066089T3 (pl) * | 2013-11-08 | 2020-04-30 | Promentis Pharmaceuticals, Inc. | Podstawione pochodne N-Acetylo-L-Cysteiny i związki pokrewne |
| CN107735094B (zh) | 2015-06-05 | 2021-05-28 | 中国医药大学 | 胱氨酸-谷氨酸转运蛋白的抑制剂的新用途 |
| US20180251431A1 (en) * | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
| WO2018107040A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof |
| US20190177295A1 (en) * | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Process for the preparation of a 1,3-disubstituted pyrazole compound |
| US20240425857A1 (en) | 2021-10-29 | 2024-12-26 | Vib Vzw | Means and Methods for Chronic Wound Healing |
| CN116535998B (zh) * | 2023-06-20 | 2024-05-17 | 安徽省阳明达新材料科技有限公司 | 一种热熔复合石材玻璃耐热eva胶片的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1493697A1 (de) * | 1965-02-25 | 1969-11-20 | Hoechst Ag | Verfahren zur Spaltung von Thiolestern aromatischer Carbonsaeuren |
| IT1194117B (it) | 1981-11-20 | 1988-09-14 | Isnardi Pietro & C Spa | Derivati salicilici di n-acetilcisteina |
| CN85107378A (zh) | 1984-09-13 | 1987-03-18 | 陶氏化学公司 | 从原煤中回收有用煤的起泡剂组合物和泡沫浮选方法 |
| US5637616A (en) | 1993-06-18 | 1997-06-10 | Arcturus Pharmaceutical Corporation | Method for treating diseases mediated by proteases |
| AU1447095A (en) | 1993-12-30 | 1995-07-17 | Arcturus Pharmaceutical Corporation | Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways |
| WO1995034303A1 (en) | 1994-06-13 | 1995-12-21 | Arcturus Pharmaceutical Corporation | Method for the treatment, prevention or minimization of hair loss |
| JP3608021B2 (ja) * | 1996-09-05 | 2005-01-05 | 参天製薬株式会社 | 新規含硫黄アミノ酸誘導体 |
| KR19990078146A (ko) | 1998-03-24 | 1999-10-25 | 마키노 아라타 | 프로필렌계 수지 조성물 및 이를 사용한 연신필름 |
| JP2002519341A (ja) * | 1998-06-29 | 2002-07-02 | パーカー ヒューズ インスティテュート | 強力な抗がん剤としてのアルキルケトン類 |
| AU6314200A (en) * | 1999-07-26 | 2001-02-13 | Toray Industries, Inc. | Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient |
| AU2002333018B2 (en) | 2001-09-27 | 2006-08-31 | The Mental Health Research Institute Of Victoria | Modulation of physiological processes and agents useful for same |
| CA2478066C (en) | 2001-12-04 | 2009-09-08 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| CN1233629C (zh) | 2002-11-22 | 2005-12-28 | 贵州省中国科学院天然产物化学重点实验室 | 具有神经营养作用的硫酯类化合物及其它的合成方法和应用 |
| FR2856592B1 (fr) | 2003-06-27 | 2008-04-25 | Oreal | Composition cosmetique a base de percuseur(s) de radical thiyl pour la deformation permanente des fibres keratiniques |
| JP2008538586A (ja) | 2005-04-21 | 2008-10-30 | グレン エー． ゴールドスタイン， | 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| WO2007042816A1 (en) | 2005-10-12 | 2007-04-19 | Biolipox Ab | Benzoxazoles useful in the treatment of inflammation |
| CN101547703A (zh) * | 2006-10-03 | 2009-09-30 | 加林制药公司 | S-亚硝基硫醇化合物和相关衍生物 |
| US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
| WO2009100431A1 (en) * | 2008-02-07 | 2009-08-13 | Marquette University | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
| WO2009137251A2 (en) | 2008-04-16 | 2009-11-12 | Marquette University | Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
| US8524772B2 (en) | 2008-05-09 | 2013-09-03 | Tiara Pharmaceuticals, Inc. | Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation |
| AU2010224866C1 (en) | 2009-03-16 | 2015-01-15 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| EP3138838A1 (en) | 2010-01-29 | 2017-03-08 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US8815905B2 (en) | 2010-03-10 | 2014-08-26 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
| EP2614821B1 (en) | 2010-09-06 | 2016-11-09 | SNU R & DB Foundation | Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof |
| CA2816609A1 (en) * | 2010-11-12 | 2012-05-18 | Promentis Pharmaceuticals, Inc. | S-t-butyl protected cysteine di-peptide analogs and related compounds |
| WO2012065110A2 (en) | 2010-11-12 | 2012-05-18 | Promentis Pharmaceuticals, Inc. | S-protected cysteine analogs and related compounds |
| AU2012208283B2 (en) | 2011-01-20 | 2017-01-05 | Oneday - Biotech And Pharma Ltd. | Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof |
| CA2842106A1 (en) | 2011-07-28 | 2013-01-31 | Promentis Pharmaceuticals, Inc. | Cysteine prodrugs |
| WO2014209412A1 (en) | 2013-06-29 | 2014-12-31 | Viva Pharmaceutical, Inc. | N-acetyl l-cysteine chelates and methods for making and using the same |
| US20150038586A1 (en) | 2013-07-10 | 2015-02-05 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of penetrating head injury |
| US20150133558A1 (en) | 2013-10-15 | 2015-05-14 | Glenn A. Goldstein | Use of n-acetylcysteine amide for decreasing intracranial pressure |
| PL3066089T3 (pl) * | 2013-11-08 | 2020-04-30 | Promentis Pharmaceuticals, Inc. | Podstawione pochodne N-Acetylo-L-Cysteiny i związki pokrewne |
| US20150209310A1 (en) | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or low impact brain trauma |
| US20150209309A1 (en) | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc | Naca for the treatment of chronic or acute cognitive dysfunction |
-
2014
- 2014-11-07 PL PL14802771T patent/PL3066089T3/pl unknown
- 2014-11-07 EP EP14802771.7A patent/EP3066089B1/en active Active
- 2014-11-07 ES ES14802771T patent/ES2765236T3/es active Active
- 2014-11-07 HU HUE14802771A patent/HUE048345T2/hu unknown
- 2014-11-07 DK DK14802771.7T patent/DK3066089T3/da active
- 2014-11-07 JP JP2016528225A patent/JP6691044B2/ja active Active
- 2014-11-07 WO PCT/US2014/064581 patent/WO2015070034A1/en not_active Ceased
- 2014-11-07 SI SI201431469T patent/SI3066089T1/sl unknown
- 2014-11-07 US US14/535,953 patent/US9012674B1/en active Active
- 2014-11-07 US US14/535,855 patent/US9630937B2/en active Active
- 2014-11-07 AU AU2014346591A patent/AU2014346591B2/en not_active Ceased
- 2014-11-07 LT LTEP14802771.7T patent/LT3066089T/lt unknown
- 2014-11-07 EP EP19207221.3A patent/EP3674297A1/en not_active Withdrawn
- 2014-11-07 PT PT148027717T patent/PT3066089T/pt unknown
- 2014-11-07 CA CA2929655A patent/CA2929655C/en active Active
-
2017
- 2017-03-15 US US15/459,840 patent/US10112897B2/en active Active
- 2017-04-07 US US15/481,728 patent/US10358414B2/en active Active
- 2017-08-04 ZA ZA2017/05288A patent/ZA201705288B/en unknown
- 2017-11-06 JP JP2017213633A patent/JP6559756B2/ja active Active
-
2018
- 2018-12-21 AU AU2018282446A patent/AU2018282446B2/en not_active Ceased
-
2019
- 2019-06-17 US US16/443,793 patent/US10961187B2/en active Active
-
2020
- 2020-04-08 JP JP2020069560A patent/JP6952825B2/ja active Active
- 2020-10-21 AU AU2020257084A patent/AU2020257084A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/216,285 patent/US20210395194A1/en not_active Abandoned
- 2021-09-27 JP JP2021156357A patent/JP7170811B2/ja active Active
-
2023
- 2023-10-17 US US18/488,215 patent/US20240059649A1/en active Pending